PML and acute myeloid leukemia: A tissue editing approach tailored to the treatment of AML comprising low-dose azacitidine (AZA), pioglitazone, and all-trans retinoic acid (ATRA) could induce hematologic or molecular complete remission in non-promyelocytic leukemia (non-PML) AML by inducing differentiation of blasts to granulocytes, which has also been corroborated in vitro (Figure 3) [12,44,50].